Both murine and human LSCC tumor cells were resistant to cisplatin, and inhibition of NF-κB signaling using either gliotoxin or 5Z-7-oxozeaenol resulted in sensitization of LSCC tumor cells to cisplatin chemotherapy, suggesting a crucial role of increased NF-κB signaling in the chemotherapy response of LSCC. The gene discussed is NFKB1; the disease is neoplasm.